Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells.
Tributyrin, a prodrug of natural butyrate, has been evaluated with an aim to overcome pharmacokinetic drawbacks of natural butyrate as a drug, i.e., its rapid metabolization and inability to achieve pharmacologic concentrations in neoplastic cells. We studied the effects of tributyrin on growth, differentiation and vitamin D receptor expression in Caco-2 cells, a human colon cancer cell line. Tributyrin was more potent in inhibiting growth and inducing cell differentiation than natural butyrate. The effect was further enhanced after addition of physiologic concentrations of dihydroxycholecalciferol [(OH)2D3]. The synergistic effect of tributyrin and (OH)2D3 in Caco-2 cells was due to tributyrin-induced overexpression of the vitamin D receptor, as measured by reverse transcriptase-polymerase chain reaction. Treatment with tributyrin increased binding of (OH)2D3 to its receptor 1.5-fold, without any change in receptor affinity. We conclude that tributyrin may, at least in part, exert its growth-reducing and differentiation-inducing effect in Caco-2 cells by an upregulation of the vitamin D receptor; this may provide a useful therapeutic approach in chemoprevention and treatment of colorectal cancer by the two nutrients occurring naturally in human diet.
Gaschott
T
T
2nd Department of Medicine, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.
Steinhilber
D
D
Milovic
V
V
Stein
J
J
D000469:Alkaline Phosphatase / Q000032:analysis; D002087:Butyrates / Q000494:pharmacology; D018938:Caco-2 Cells / Q000187:drug effects* / Q000473:pathology; D002452:Cell Count; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004100:Dihydroxycholecalciferols / Q000494:pharmacology*; D015536:Down-Regulation; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D011355:Prodrugs / Q000494:pharmacology*; D014280:Triglycerides / Q000494:pharmacology*
D002087:Butyrates; D004100:Dihydroxycholecalciferols; D004338:Drug Combinations; D011355:Prodrugs; D014280:Triglycerides; D004247:DNA; D000469:Alkaline Phosphatase; C005830:tributyrin